HPM Department News

Gellad sceptical that drug company outcomes-based pricing can lower costs

Drug policy researcher WALID GELLAD says the outcomes-based contracts are being viewed as the solution to the drug-price problem, and they’re not going to be, at least not in the short term. The deals don’t stop drug companies from charging high starting prices for new drugs or from steadily raising prices for older drugs. Any rebates or discounts in outcomes-based contracts are off an already inflated number. He favors other ways to curb drug co... 

Accreditation president visits HPM to learn more about MHA program

Anthony Stanowski, president and CEO of the Commission of Accreditation of Healthcare Management Education (CAHME), visited the Department of Health Policy and Management on Wednesday, August 30. His main goals of the visit were to learn more about our MHA program and to stress the importance of CAHME accreditation in advancing the quality of health care management education. 

Meet Chandler Caufield (HPM '20), Dean's Scholar

Pittsburgh native and MHA/MBA student CHANDLER CAUFIELD (HPM ’20) was familiar with the city’s burgeoning medical sector buoyed by world-class hospitals and universities; however, it wasn’t until she worked in the industry that she discovered health care was the field for her. "Eventually, I landed on health care administration because it seemed like the perfect intersection of my interests and skills as well as my passion for improving the pati... 

Gellad on the cancer drug pricing firestorm

AXIOS - Doctor and health policy professor WALID GELLAD said the real question is why a potential breakthrough drug that has some question marks about effectiveness should cost more than proven life-saving measures like bone marrow or kidney transplants. “This is an amazing therapy, but there has to be a limit at which point companies can no longer charge desperate patients, or taxpayers, enormous sums.” 

Shapiro interviewed about growing better, not bigger

BECKER’S HOSPITAL REVIEW - Pitt Public Health alumnus LOU SHAPIRO (HPM ’84), CEO of the New York based Hospital for Special Surgery, talks about how he plans to stay competitive in an increasingly consolidated healthcare landscape and what it means to grow better instead of bigger. 

Hernandez says evolocumab not cost-effective at current price

TCTMD - Two new analyses call into question the cost-effectiveness of adding the PCSK9 inhibitor evolocumab to statin therapy in patients with atherosclerotic cardiovascular disease. Pitt Public Health alumna INMACULADA HERNANDEZ (HPM ’16) noted that the conclusions of the two papers are the same: the drug’s cost “is way above what we usually considered cost-effective in this country.” 

Donohue's research says hospitals could do more for survivors of opioid overdoses

NPR - Using claims data from Medicaid patients in Pennsylvania from 2008 to 2013, HPM’s JULIE DONOHUE looked at prescription opioid use and medication-assisted treatment rates before and after overdoses. The study's senior author found that “This is a time when people are vulnerable, potentially frightened by this event that’s just occurred and amenable to advice, referral, and treatment recommendations. It’s safe to characterize it as a missed o... 

HPM grad Rick Anderson guides St. Luke's hospitals through decades of change

THE MORNING CALL -- After over 30 years at the helm of St. Luke's University Health Network, RICHARD A. ANDERSON (HPM '71) is among a handful of the longest-serving top health care executives nationally. With Anderson at the helm, St. Luke's has grown from a single hospital with an annual budget of $73 million to a diversified health care organization with more than $1 billion in revenues and 9,000 employees, making it the second-biggest employer... 

Donohue on the causes of explosive growth in opioid prescription sales

HUFF POST - What caused the explosive growth in opioid sales? The FDA and TV advertising. In 1997, the FDA rules governing pharmaceutical advertising changed, allowing TV ads to name both the drug and what was for, while only naming the most significant potential side effects. After that, the number of TV ads exploded. A 2009 NPR story stated “there’s an average of 80 drug ads every hour of every day on American television. And those ads clearly ... 

Broom joins HPM leadership

UNIVERSITY TIMES - The Department of Health Policy and Management has named a new vice chair of education and director of the Master of Health Administration (MHA) and MHA/MBA joint degree programs. KEVIN BROOM comes to Pitt from Saint Louis University, where he served as an assistant professor of health management and policy. Broom succeeds WESLEY ROHRER, who returned to the HPM faculty on June 30. 

CPHP’s Van Nostrand launches ELI, new award-winning legal tool for emergency volunteers

In May 2017, ELIZABETH VAN NOSTRAND and her team from the Center for Public Health Practice were honored with the Medical Reserve Corps Program National Partner Recognition Award for the development of ELI, the Emergency Law Inventory tool — a repository of statutes and regulations that impact volunteers participating in emergency response activities on the topics of liability, license reciprocity, scope of practice, and workers’ benefits. 

HPM's Gellad asked about Ohio drug price measure

BLOOMBERG - If a pharmaceutical company wants to gain access to the VA’s market, it has an incentive to offer the VA a lower price on its drugs, said HPM’s WALID GELLAD. But would drug companies simply raise their prices to the VA? 

Griffin named 2017 30 Under 30 awardee by Pittsburgh Business Times (video)

PITTSBURGH BUSINESS TIMES - Alumna LAURA GRIFFIN (HPM ’13) has been honored by Pittsburgh Business Times as a 2017 30 Under 30 award winner. Her contributions as director of network nursing operations at Allegheny Health Network has brought her to the attention of management. 

Gellad on why a money-back guarantee for drugs is a bad idea

STAT NEWS - One health plan option Trump’s administration is considering may not be much of a deal for consumers. “It’s not going to lower prices substantially, certainly not in the short term and probably not in the long term,” said WALID GELLAD, HPM assistant professor and co-director of the Center for Pharmaceutical Policy and Prescribing at Pitt. “It’s an easy way out of addressing the real complexities.” 

Meet Kristen Free (MHA '18), Gideon Scholar

"I think that Dawn left an incredible legacy. Every time I mention the foundation, I'm running into people who personally knew Dawn and every single person I runinto has a great story about her and had great interactions with her. And through all of these stories, I'm not only learning through the resources that the foundation has given me, but also through Dawn herself," said Free of how she's inspired by Gideon.   

Page 17 of 30First   Previous   12  13  14  15  16  [17]  18  19  20  21  Next   Last   

Search for an Article

Share Your News

Simply click to share news of your achievements—and those of classmates or colleagues. We’re eager to hear about and share stories of student, faculty, and alumni accomplishments. Email questions to phcomm@pitt.edu
or visit publichealth.pitt.edu/sharenews.

Share news

HPM Alumni Newsletters

Find news by department

Use the "Search for an article" field above to filter news by keyword, or follow the links below to view by department: